Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Current asthma biologics require frequent dosing.
Ultragenyx Pharmaceutical Inc. sank after the company’s experimental drug for a rare genetic bone disease failed to meet the primary endpoints in two phase 3 clinical trials. Ultragenyx dropped 41% at ...
Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) on Tuesday announced a regulatory update following a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration (FDA).
SAN FRANCISCO and SUZHOU, China, Dec. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase ...
Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease (AD). But perhaps the larger story associated with the unsurprising result is the market ...
nDepartment of Oncology and Palliative Care, Cardinale Giovanni Panico Hospital, Tricase, Italy oSection of Innovation Biomedicine—Oncology Area, Department of Engineering for Innovation Medicine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results